Request Demo
Recent blog posts
Latest Hotspot
8 min read
Postherpetic neuralgia Indication Strategy Report 2026: Nav1.7, Trials and Deals
23 July 2026
2026 Postherpetic neuralgia strategy: epidemiology, Nav1.7 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Hemiplegic migraine Indication Strategy Report 2026: CACNA1A, Trials and Deals
23 July 2026
2026 Hemiplegic migraine strategy: epidemiology, CACNA1A biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Chronic migraine Indication Strategy Report 2026: CGRP, Trials and Deals
23 July 2026
2026 Chronic migraine strategy: epidemiology, CGRP biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Transverse myelitis Indication Strategy Report 2026: IL-6R, Trials and Deals
23 July 2026
2026 Transverse myelitis strategy: epidemiology, IL-6R biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Optic neuritis Indication Strategy Report 2026: C5, Trials and Deals
23 July 2026
2026 Optic neuritis strategy: epidemiology, C5 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Anti-NMDA receptor encephalitis Indication Strategy Report 2026: FcRn, Trials and Deals
23 July 2026
2026 Anti-NMDA receptor encephalitis strategy: epidemiology, FcRn biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Miller Fisher syndrome Indication Strategy Report 2026: C5, Trials and Deals
23 July 2026
2026 Miller Fisher syndrome strategy: epidemiology, C5 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Guillain-Barré syndrome Indication Strategy Report 2026: FcRn, Trials and Deals
23 July 2026
2026 Guillain-Barré syndrome strategy: epidemiology, FcRn biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Multifocal motor neuropathy Indication Strategy Report 2026: C1s, Trials and Deals
23 July 2026
2026 Multifocal motor neuropathy strategy: epidemiology, C1s biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Secondary progressive multiple sclerosis Indication Strategy Report 2026: BTK, Trials and Deals
23 July 2026
2026 Secondary progressive multiple sclerosis strategy: epidemiology, BTK biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Primary progressive multiple sclerosis Indication Strategy Report 2026: CD20, Trials and Deals
23 July 2026
2026 Primary progressive multiple sclerosis strategy: epidemiology, CD20 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Myoclonus-dystonia Indication Strategy Report 2026: SGCE, Trials and Deals
23 July 2026
2026 Myoclonus-dystonia strategy: epidemiology, SGCE biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…